Jubilant Radiopharma recently invested $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities within its Radiopharmacies Division.
Harsher Singh, President, further explains, "I see the future of Jubilant Radiopharma as a full-service company offering novel products, services and distribution networks that rival no other and position our mission of Improving Lives through Nuclear Medicine™ well into the future."
For more information, please visit https://lnkd.in/gTmrNH6n#JubilantRadiopharma#NuclearMedicine#CardiacPETImaging#DiagnosticImaging
Should Australia look towards creating a radiopharmaceutical specific reimbursement pathway?
As it currently stands there are both MSAC and PBAC avenues but the process is fragmented and poorly understood.
The latest MSAC PSD gives clear evidence of this.
With so much investment in nuclear medicine globally, is Australia at risk of falling behind?
https://lnkd.in/gEg4AJg9
Nuclear Medicine Europe is the professional association of companies active in the nuclear medicine field across the world (notwithstanding the "Europe" in its name). Its role in the currently ongoing revolution in the nuclear medicine field with promising new therapeutic options in cancer care in full development, cannot be overestimated.
One of the major challenges the industry is facing is putting in place and securing the various supply chains and the logistics they require, not in the least the radioisotope supply.
Given my experience in the domain, I would like to strongly advocate to spend money and time on making these supply chains independent from national and international subsidies and control, instead of asking oneself how subsidies and control can stabilise these chains.
The ongoing boom in radiopharma offers an opportunity to correct mistakes from the past in which isotope production was left to national labs and heavily subsidized, creating a market which is now incapable of surviving without subsidies. The biggest example is the Mo-99 supply chain, which relies on a handful of ageing reactors throughout the world (>50% of it is coming from 2 reactors in Belgium and the Netherlands).
It is vital that radiopharmaceuticals are accepted to have a COGS of 8-12% (compared to the typically much lower COGS of other pharma products) and in that sense allow radioisotope production to become commercially viable and sustainable. Allowing the market dynamics to play its role will improve the quality of service provided by the producers and will create a viable business case for the construction of dedicated isotope production reactors.
Even without commercial reactors, assuring a proper margin for the production of these highly technological and life-saving ingredients of radiopharma can be achieved. If the reimbursement of the radioisotope is separated from the reimbursement of the pharmaceutical, the participation of all countries to the isotope production cost, proportional to their use of radiopharma products, will be assured. Today, the taxpayers of a few countries help fund the production of medical radioisotopes for the rest of the world, which is not sustainable...
The NMEu will help us to address these and many other issues at a European and even global level, creating a hopeful future for cancer patients !
On Wednesday, April 24th, the final discussion for one of the largest Kansen voor West II projects took place: FIELD-LAB. Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal.
The Kansen voor West II project, named “Advancing Nuclear Medicine, Petten FIELD-LAB,” has resulted in a state-of-the-art GMP production facility. FIELD-LAB contributes to the acceleration of the development of new nuclear medicines. This facility is utilised for the production of promising radioactive materials for the preparation of innovative nuclear medications. FIELD-LAB also ensures the development of the necessary production processes.
Significant achievements so far include a sustainable concept of a production system for two promising so-called starting materials and base material for two new therapies for cancer treatment. A tracer is being developed to better select patients for chemotherapy. Additionally, a dozen feasibility studies have been initiated for the product development of industrial parties.
#precisionmedicine#healthcareinnovation#medicine#innovation
At the heart of every RLS radiopharmacy is a team of dedicated nuclear pharmacists and personnel who take great pride in their work. Their expertise ensures that every order, without exception, is prepared, dispensed and delivered with precision. Our in-house couriers and robust delivery fleet echo this precision, assuring life-saving radiopharmaceuticals arrive where they are needed and when they are needed, without fail. https://rls.bio/#NuclearPharmacy#Radiopharmacy#nuclearmedicine
The European Association of Nuclear Medicine (EANM) and Nuclear Medicine Europe (NMEU) express disappointment over the recent European Parliament vote on the #Pharmaceutical#Regulation and Directive, which did not incorporate their proposed amendments aimed at updating the regulatory framework for #radiopharmaceuticals.
Despite the pivotal role #NuclearMedicine plays in modern healthcare, especially in cancer care as recognized by EU initiatives like the SAMIRA Action Plan, the current legislative approach fails to acknowledge the significant advancements in radiopharmaceuticals since 2004. This oversight poses challenges to the industry and clinical sectors, leading to uncertainties and reduced availability of radiopharmaceuticals across Europe.
EANM and Nuclear Medicine Europe advocate for a regulatory framework that aligns with the evolving landscape of Nuclear Medicine, emphasizing the need for updated definitions and provisions to support the growth and accessibility of radiopharmaceuticals. They call upon policymakers to reconsider these developments and ensure that the revised legislation reflects the advancements in Nuclear Medicine, ultimately benefiting patients across the EU.
Download the full statement : https://lnkd.in/ewenrYx
“𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗮𝘀𝗸 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗖𝘂𝘀𝘁𝗼𝗺𝗲𝗿 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝘀𝗼𝘂𝗻𝗱𝗶𝗻𝗴 𝘀𝗮𝗹𝗲𝘀𝘆?”
What a fantastic 1 x day Sales Masterclass that tackles that very question.
Working with this terrific tribe of Sales professionals at Xiel Ltd talking about Nuclear medicines and Radiotherapy….
But most of all….
How to have better, quality conversations with Customers with our AvA-V bespoke practical toolkit! 🛠
𝗪𝗮𝗻𝘁 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗵𝗼𝘄 𝘄𝗲 𝗱𝗼 𝗶𝘁?
DM me and let’s just have a conversation.
Happy Wednesday folks!
#sales#training#rapport#trust#salesquestions#WeAreAvAVhttps://lnkd.in/eQbK3NfH
Nuclear Medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of a variety of diseases.
Specialized formulation and dispensing equipment is essential for safe formulation, dispensing, packing and inspection of these products.
PBL’s N-R&D Integrated Formulation & Dispensing “Hot Cell” system featured in this video covers all your needs for safe and efficient production of Nuclear Medicines.
IMAS INGENIOUS MACHINES proudly represents PBL in South Africa. Get in touch with Paul Adams 🇿🇦 or Lyn-Ann Adams of IMAS, or Andrea Gui of PBL, for more information.
#southafrica#pharmaceuticalindustry#pharmaceuticalmanufacturing#injectables#parenterals#nuclearmedicine
Sr. Manager Quality Compliance - PET cGMP at Jubilant Radiopharma
1moCongratulations to the leadership and the entire team at Jubilant - helping to move PET into the future!